Skip to main content

Repositioning Drugs for Parkinson’s Disease

World Pharma Congress - Philadelphia

Drug repositioning refers to applying an existing compound (either an approved drug or a clinical candidate in testing) for one indication to another indication and offers several advantages over traditional drug discovery: reduced cost, risk and time to market. This talk will describe the initiatives undertaken by the Michael J. Fox Foundation for Parkinson's research, in identifying and funding the repositioning of clinically safe compounds from other indications to Parkinson's disease.

Authors: Kuldip Dave

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.